Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Tri... via @YouTube
#CandelTherapeutics #viral #immunotherapy #ProstateCancer #lungcancer #pancreatic cancer #glioblastoma
President and CEO, @paulpetertak, MD, PhD, FMedSci, shares insights on our CAN-3110 clinical program for recurrent #glioblastoma with DocWire News.
Watch to learn more.
https://docwirenews.com/post/paul-peter-tak-ceo-of-candel-therapeutics-discusses-the-treatment-of-glioblastoma
$CADL
Only 15-40% of advanced #NSCLC patients respond to standard ICIs.
This #HealthyLungMonth, we're highlighting the need for new treatments.
Candel is testing CAN-2409, a viral immunotherapy showing promise in progressive disease despite ICI treatment.
https://www.candeltx.com/patients/#step-25
